Brought to you by 
Daiichi Pharmaceutical Co. Ltd.
www.daiichipharm.co.jp
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Daiichi Pharmaceutical Co. Ltd.
Turnaround For Spectrum’s Poziotinib As Phase II Cohort 2 Meets Endpoint
Spectrum is set to discuss NDA submission plans with the US FDA after unveiling positive top line results from Cohort 2 of the Phase II ZENITH20 study with poziotinib, in pretreated NSCLC patients with HER2 exon 20 insertion mutations. The drug, licensed from Hanmi, failed in the Cohort 1 part of the trial earlier this year.
Company Information
- Industry
- Pharmaceuticals